A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease

Status Completed

Clinical Trial Summary

The main goal of this study is to learn how teprotumumab will be processed in the body (Pharmacokinetics) subcutaneously and whether it is safe and tolerable after administration into adult patients with thyroid eye disease.

Clinical Trial Description

This is a Phase 1b, open-label, multicenter trial to assess the PK, safety, and tolerability of a single SC dose of lyophilized teprotumumab and high concentration formulation teprotumumab in participants with thyroid eye disease. Approximately 6 participants (in Cohort 1) and approximately 10 participants (in Cohort 2) who meet the trial eligibility criteria will be enrolled in a 1:1 ratio. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06389578
Study type	Interventional
Source	Horizon Pharma USA, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	July 14, 2022
Completion date	September 12, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04583735` - A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease	Phase 4
Active, not recruiting	`NCT05002998` - TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study	Phase 4
Withdrawn	`NCT02422368` - The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease	Phase 2/Phase 3
Completed	`NCT03298867` - Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study	Phase 3
Recruiting	`NCT05987423` - A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease	Phase 3
Recruiting	`NCT06112340` - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)	Phase 2/Phase 3
Recruiting	`NCT05517447` - Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease	Phase 3
Terminated	`NCT04737330` - A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)	Phase 3
Recruiting	`NCT05517421` - Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease	Phase 3
Recruiting	`NCT04311606` - Anti-VEGF Therapy for Acute Thyroid Eye Disease	Phase 2
Recruiting	`NCT06106828` - A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease (SatraGO-2)	Phase 3
Recruiting	`NCT06021054` - A Randomized, Double-masked, Placebo-controlled Safety, Tolerability, and Efficacy Study of VRDN-001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Participants With Chronic Thyroid Eye Disease (TED)	Phase 3
Not yet recruiting	`NCT06413043` - Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy	N/A
Not yet recruiting	`NCT06401044` - A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease	Phase 1
Recruiting	`NCT06367517` - Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)
Recruiting	`NCT06275373` - The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Enrolling by invitation	`NCT05241626` - AS-OCT of the Cornea in Thyroid Diseases
Active, not recruiting	`NCT05776121` - Study of ZB001 in Chinese Patients With Thyroid Eye Disease	Phase 1
Recruiting	`NCT04359979` - Tamsulosin for Thyroid Lid Retraction	N/A
Recruiting	`NCT06226545` - A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease	Phase 2